Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Gerresheimer AG
  6. News
  7. Summary
    GXI   DE000A0LD6E6

GERRESHEIMER AG

(GXI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gerresheimer : with innovative SensAIR platform for first drug delivery device for biologics

05/03/2021 | 05:33am EDT
With SensAIR, Gerresheimer presents for the first time a new platform for on-body infusion pumps which can administer drugs of higher viscosity, such as monoclonal antibodies (mAb), in precise doses and safely.

Düsseldorf, May 03, 2021. With SensAIR, Gerresheimer presents for the first time a new platform for on-body infusion pumps which can deliver drugs of higher viscosity, such as monoclonal antibodies (mAb), with precise dosing and safely. The aim is to provide patients with the best possible support in the subcutaneous delivery of large-volume biologics. The ready-to-use SensAIR On-Body Infusor is easy to use and enables patients to start medication in a self-determined manner in familiar surroundings, for example at home. The SensAIR On-Body Infusor can be adapted to many medications of different viscosities and different requirements. This applies to the size of the medical device as well as to the needle used, variable cartridge sizes and possible connectivity, for example to the patient's smartphone. Together with Gerresheimer's One-Stop-Shop quality promise, which includes a solution from the cartridge to the drug delivery device from a single source, SensAIR enables safe and optimized delivery of biologics.

'Everyone benefits from SensAIR: patients, their relatives and also doctors. This device is an innovative medical device which, when worn on the body, delivers up to 20 ml of biologics subcutaneously to the patient,' says Oliver Haferbeck, Head of the Advanced Technology & Innovation Unit at Gerresheimer and CEO of Sensile-Medical AG. He explains that patients gain significantly in quality of life because they can administer their medication themselves at home. The ready-to-use concept ensures that the patient does not have to carry out any lengthy and complicated preparation steps, but can operate the device simply and safely.

More quality of life for the patient

To date, many patients with a wide variety of indications have to endure long and stressful infusions in a hospital setting to treat their condition. How much easier would it be if patients could carry out the treatment at home? SensAIR makes life easier for these patients, as they can care for themselves over a longer period of time and - depending on the indication - only need to visit the doctor or hospital for check-ups.

SensAIR is an innovative product platform for the infusion of large-volume and highly viscous biologics. The technology, function, design and construction of the platform were jointly developed by Gerresheimer specialists and the product is supplied from a single source.

Safety and cost efficiency

The SensAIR Infusor is characterized by a simple and safe concept which can be cost-effectively adapted to different needs, especially patient needs. Gerresheimer thus offers a platform solution which provides a wide range of options with regard to the biologic to be applied; starting with the drug flow rate (0.15-1.00 ml/min), through type (for example glass cartridge) and volume (up to 20ml) of the primary packaging, to connectivity.

With this focus, SensAIR is attractive to the market even with varying quantities of devices per year, as existing developments and processes can be adapted in the shortest possible time. The existing technologies and know-how, which have already proven themselves in the market, are consistently pursued in SensAIR. This is a significant advantage in terms of time-to-market, among other things by quickly enabling clinical trials.

Gerresheimer is therefore both a partner for the SensAIR device and a supplier and manufacturer of the primary packaging, i.e. the cartridge containing the active ingredient. This represents significant added value as a long-term partner and system supplier.

https://www.gerresheimer.com/en/drug-delivery-systems/platform-solutions/on-body-infusor

About Gerresheimer

Gerresheimer is the global partner for pharmaceutics, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging and drug delivery devices. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generates annual sales of more than €1.4 billion. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.

Disclaimer

Gerresheimer AG published this content on 03 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 May 2021 09:32:10 UTC.


ę Publicnow 2021
All news about GERRESHEIMER AG
06:24aDGAP-PVRá : Gerresheimer AG: Release according to -2-
DJ
06:24aGERRESHEIMER AG : Release according to Article 40, Section 1 of the WpHG [the Ge..
EQ
06:24aDGAP-PVRá : Gerresheimer AG: Release according to Article 40, Section 1 of the W..
DJ
06/17GERRESHEIMER AG : Correction of a release from 20/03/2020 according to Article 4..
EQ
06/17DGAP-PVRá : Gerresheimer AG: Correction of a -2-
DJ
06/17GERRESHEIMER AG : Correction of a release from 03/03/2020 according to Article 4..
EQ
06/17DGAP-PVRá : Gerresheimer AG: Release according to -2-
DJ
06/17GERRESHEIMER AG : Release according to Article 40, Section 1 of the WpHG [the Ge..
EQ
06/15GERRESHEIMERá : is building at the Pfreimd location
PU
06/11GERRESHEIMER AGá : Goldman Sachs reiterates its Buy rating
MD
More news
Financials
Sales 2021 1 470 M 1 756 M 1 756 M
Net income 2021 113 M 134 M 134 M
Net Debt 2021 933 M 1 115 M 1 115 M
P/E ratio 2021 26,1x
Yield 2021 1,38%
Capitalization 2 933 M 3 492 M 3 503 M
EV / Sales 2021 2,63x
EV / Sales 2022 2,45x
Nbr of Employees 9 904
Free-Float 100%
Chart GERRESHEIMER AG
Duration : Period :
Gerresheimer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GERRESHEIMER AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 93,40 €
Average target price 102,14 €
Spread / Average Target 9,35%
EPS Revisions
Managers and Directors
NameTitle
Dietmar Siemssen Chief Executive Officer
Bernd Metzner Chief Financial Officer
Axel Herberg Chairman-Supervisory Board
Theodor Stuth Member-Supervisory Board
Udo Johannes Vetter Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
GERRESHEIMER AG6.44%3 492
ABBOTT LABORATORIES1.34%197 156
MEDTRONIC PLC8.19%170 503
BECTON, DICKINSON AND COMPANY-3.96%69 890
HOYA CORPORATION4.06%49 121
ALIGN TECHNOLOGY, INC.13.16%47 855